Q2 2023 Catalent Inc Earnings Call
By approximately 700 employees and expect to incur cumulative employee charges between 14 and $20 million.
As a result of our restructuring plans, we expect to deliver annualized run rate savings in the range of $75 million to $85 million over calendar 2023, with approximately half of the savings to be realized in the second half of our fiscal 'twenty three.
In addition, we expect to generate savings from other cost efficiency and procurement programs above and beyond the reduction of approximately 700 staff that are expected to generate additional annualized savings of tens of millions of dollars.
Now, let's discuss our segment performance, where commentary around segment growth will be in constant currency.
As shown on slide 10-Q, two net revenue in our biologics segment of $580 million decreased 7% compared to the second quarter of 2022.
The decline is primarily driven by lower year on year Covid related demand.
Q2 results included $54 million from the vaccine take or pay settlement disclosed last quarter.
The decline in coal revenue was partially offset by growth across our non COVID-19 programs with gene therapy being the strongest growth contributor.
Total non COVID-19 revenue growth for the biologics segment was more than 10% down from Q1.
The non COVID-19 revenue growth rate in biologics is expected to return to the higher levels of growth. We saw in the first quarter driven by increased demand at our gene therapy offering.
Easier comparisons in Brussels, and uptake in demand for several drug product programs.
The segment EBITDA margin of 31, 3% was slightly higher than the 31, 1% reported in the second quarter of fiscal 2022.
Year over year margin expansion is mainly attributable to the vaccine take or pay settlement that we discussed during our Q1 call.
As shown on slide 11, our pharma and consumer health segment generated net revenue of $570 million, an increase of 3% compared to the second quarter of fiscal 2022 with segment EBITDA down 3% over the same period last fiscal year.
The segment's revenue growth was primarily driven by the recently acquired Metrix business, which contributed three percentage points to the segment's top line and four percentage points to the bottom line.
There were a number of moving pieces that drove organic PCH results in the quarter.
As you can see on the revenue stream chart, our development services and clinical supply services showed strong growth, but that was offset by a decline in our manufacturing and commercial supply revenue.
Within the commercial stream growth and over the counter cold and cough products were offset by a decline in prescription products and lower consumer.
He spent for nutritional supplements, such as gummies and other premium formats.
The segment's EBITDA margin of 23, 7% was lower by roughly 170 basis points year over year from the 25, 4% recorded in the second quarter of fiscal 2022.
Year over year margin decline was a result of cost inflation and unfavorable product mix across the network.
We expect the PCH segment organic growth rate to modestly increase in the back half of the year, particularly in the fourth quarter due to continued demand for clinical supply services and increased volume for prescription products, most notably in our <unk> delivery platform.
Moving to consolidated adjusted EBITDA on Slide 12, our.
Our second quarter, adjusted EBITDA decreased 9% to $283 million or 24, 6% of net revenue.
On a constant currency basis, our second quarter, adjusted EBITDA declined 6% compared to the second quarter of the prior year.
As shown on slide 13 second quarter, adjusted net income was $122 million or <unk> 67 per diluted share compared to adjusted net income of $163 million.
Or <unk> 90 per diluted share in the second quarter a year ago.
Slide 14 shows our debt related ratios and other capital allocation priorities.
Catalyst net leverage ratio as of December 31, 2022 was three seven times up from the three two times as of September 32022, due to drawdowns on our revolving credit facility to fund the matrix acquisition, which closed October three 2022.
Net leverage as of December 31, 2021 was two eight times and our long term net leverage target ratio remains at three eight times.
Our combined balance of cash cash equivalents in marketable securities as of December 31, 2022 was $470 million, an increase of $125 million from September 32022.
Although our free cash flow generation is improving there is still work to do within this remains a significant focus of the management team.
For the second quarter, we were pleased to generate free cash flow of approximately $45 million makes.
Making the first time in several quarters that we generated positive free cash flow.
This was a result of more disciplined capex spending as previously discussed our strong quarter of AR collections and a rise in contract liabilities due to upfront payments from several customers. We continue to expect our fiscal 'twenty three capex as a percentage of revenue to be between 10 and 11%.
Free cash flow was again negatively impacted by our strategic decision to maintain increased inventory levels, which we do not expect to change in the short term due to our concerns about the stabilization of the global supply chain and our commitments to our customers to deliver reliable supply.
Note that approximately 15% of our inventory includes work in process with the remainder being raw materials and supplies. As a reminder, we do not include our customers finished goods in our inventory balance.
As noted in the past contract assets are generated as revenue is recorded based on percentage of completion versus entirely on batch release as it is for typical commercial programs.
As of December 31, 2022, our contract asset balance was $513 million, a sequential increase of $52 million.
This increase was primarily driven by gene therapy programs in the development stage for which the cash conversion cycle is longer given the duration of the manufacturing and release testing process, which can take multiple quarters from start to finish.
We have a number of internal initiatives in place to optimize the manufacturing cycle time.
In addition improvement of our contract terms as a potential lever that could reduce our cash conversion cycle and contract asset balance.
What the batch subject to contract asset treatment is released to the customer and the invoices sent to the customer and the related balance moves from contract assets to accounts receivable.
As you will read in our 10-Q filed today, we have two strategic customers that collectively represent approximately 35% of our aggregate net trade receivables and current contract asset values in the second quarter.
Separately and unrelated to our balance sheet during the second quarter, we had two customers that each accounted for more than 10% of net revenue.
The majority of revenue from these customers were derived from Covid programs.
Now, we turn to our financial outlook for fiscal 2023 as outlined on slide 15.
We are reiterating our guidance ranges for the full year. However.
However, I would like to highlight some of the changes in the assumptions that underpin our projected full year results.
First as mentioned earlier on the call. Our Cobra business is tracking ahead of our expectations with full year revenue now expected to be above $600 million.
Third to our previous estimate of approximately $550 million.
Based on current visibility, we expect Q3 to have a minimal COVID-19 contribution and be our lightest COVID-19 quarter by far in fiscal 'twenty three.
However, looking to Q4, we expect revenue to sequentially increase based on customer demand related to the fall booster season.
Second as consumer discretionary spend challenges continue our projections for consumer health products, including Gummies had been negatively impacted but are now anticipated to be down when compared to prior year levels.
Third we continue to see increased strength in gene therapy with a significant program further ramping late in our third quarter, which we expect to lead to a notable step up in Q4 revenue and earnings.
Fourth our non Covid business outlook remains strong with the second half of the year expected to be in line with the growth. We saw in the first quarter, which was more than 20% on an organic constant currency basis for the full year non COVID-19 growth is expected to be in the high teens.
Fifth from a quarterly perspective, we expect Q3 revenue to be roughly in line with the reported Q2 results. However, as Q2 included the $54 million take or pay agreement, we project margins to be sequentially down from Q2 to Q3 than expanding as we get into the fourth quarter.
Finally, the U S. Dollar has weakened since our last report, resulting in a modest FX tailwind when compared to our November assumptions.
Operator, I would now like to open the call to questions.
Yes.
Thank you.
I'd like to ask a question. Please do so now by pressing star followed by the number one on your telephone keypad. If you change your mind I would like to be removed from the key staff.
Please limit yourself to one question and one follow up and then please return to the key if you have any further questions.
Our first question today comes from Jacob Johnson with Stephens. Please go ahead Jake it.
Hey, good morning, Thanks for taking the questions maybe for Tom following up on those last comments around the guidance.
The updated guidance assumes kind of less of an FX headwind slightly higher revenue that would seem to imply maybe tempering slightly or organic growth.
Growth versus prior expectations.
Maybe maybe some of that is related to the actual but any areas where you built in some conservatism there and then still failing wide range for the guidance for this year, just any kind of puts and takes you'd call out as we think about the high and low end of guidance.
Sure Jacob Thanks for the question look I would say we did see as we.
You mentioned on the call non COVID-19 organic growth in the first half.
The fiscal year at about 12% it was down in the second quarter in comparison to where we saw in first quarter levels. However, as we get into the second half of the year. We have line of sight, which is very typical at this point in time to have strong visibility to just the remaining five or six months that we have in the fiscal year from those volumes so expecting.
To see non COVID-19 growth in the second half more in line with what we saw in the first half again in that 20% range and that will bring our full year.
Non COVID-19 related growth to be in the mid teens as they as I mentioned on the call I think we continue to be.
Very bullish on the demand profile, we see around gene therapy programs as well as on the drug product side of the business those would be the main contributors that we would see to the change in organic non COVID-19 related growth in the second half of the year and we were able to still hold our guidance range and pull back around.
The assumptions on the PCH side of the business, whereas we mentioned we continue to see some pressures.
Particularly when it comes to discretionary spend.
On the on.
The gummies.
And I would say just nutraceutical products across both Softgel and drug companies in the in the second half of the year. You did mentioned FX that is I would say a modest tailwind for us here, but given where we are in the year and only the modest weakening of the dollar we saw in comparison to the euro and GBP not a significant uplift.
There.
I would say as you think about the range that we have out there for us.
For the full year guide I think it really comes down to execution in terms of where we land within the range as I said at this point in time, we typically do have very strong visibility to the demand profile across the business and it comes down to execution across the across our network and we certainly I would say built in some natural hedge just based on the.
Normal.
Execution related hiccups you can see in this business when you operate 55 sites across the across the globe.
Got it that's helpful. And then just my follow up maybe browse Andrea just on the.
Agreement with Madonna first congratulations.
Can you just talk about this relationship kind of beyond FY2023 as we and investors think about kind of the epidemic COVID-19 revenue opportunity, but also the non COVID-19 work you could do with them, perhaps with RSC influence over all of these things are kind of blurring together, but just kind of any any thoughts about about that relationship kind of COVID-19.
Exco the dynamics.
Sure look first of all I would say that our relationship with more thereby it goes back many many years. So so we started to work with them to win.
At the very beginning of that journey in two.
2015, 2016, and so we are very very pleased all of these relationships grow and continues to grow into the future.
I believe that the way that he got the vaccine that we have.
Keeping that network to be in the best position to serve.
What he is going to be a seasonal product going forward.
So that on one hand that we can finish capacity across our network.
In multiple sites and at the same time maintained a level of efficiency productivity, which which is important to us right and that this is the best way to do it when it comes to seasonal demand.
On the other day and very very excited about the participating because of these.
Promising new platforms.
We continue to support them both on the clinical side, but also embedding across different formats for what the market might make wise. So we are very excited about this relationship we've always been.
In partnership with them and we are very pleased that you know.
These relationships will continue to grow as the in the next few years.
Got it thanks for taking questions.
Our next question comes from the late cycle of Barclays. Please go ahead Nick.
Hi, This is Sam on for Luke.
Just a couple of questions here.
With a couple of quarters left in our fiscal year.
What gets you guys too.
Low to high end of the EBIT guidance range.
Does that threat.
Factor in there with their approval.
We can just start off there.
Sure.
So obviously, we did mentioned the threat of the relationship and the <unk> date being in late May I would say very little downside risk associated with direct outside of just normal execution here.
Here just given the fact that at this point in time, we really do have very strong visibility as I mentioned earlier.
The volume related to that program and quite frankly related to many of the larger development and commercial programs that we have across the network as I said.
We continue to manage the business to a higher set of financial targets internally as we commit to that we commit to externally, which is which is very standard and as I think about the range of our of our guidance for next year I think execution really drives where in that range do we land.
Versus any material changes in demand just based again on where we are in the fiscal year and the amount of visibility we have around the demand profile across both.
Specialty across our biologics business, but I would say even across our clinical.
Supply and pharma side of our of our PPD.
PCH segment, the one area, where I would say, we have a little more variability, but again.
Relatively.
Reduced outlook related to the consumer health side of our PCH business is certainly already factored in to the to.
The guidance as well.
Thanks, that's helpful and then on a follow up.
So the topline guide implies a bit of a step down what got materially worse and is that kind of split between PTH and biologics.
And that also implies a <unk> step up.
Outside of historical norms is that just from Covid any color around that would be helpful. Thank you.
Sure. So we did highlight in our prepared remarks that where we do see a change in outlook is primarily driven on the PCH side of the business and I would say the consumer health part of that business really the area, where we have.
Where we have de risked I.
I'd say from a Covid standpoint, Theres certainly is a step up here in our fourth quarter as we mentioned, we have orders and visibility too.
A booster season in the fall with demand ramping up across multiple formats.
Major strategic customer in that fourth quarter. So given the fact that we do expect to see minimum COVID-19 revenue in our third quarter based on what we have visibility to.
Significant demand in our fourth quarter, we wanted to ensure that that point was.
As communicated.
Two two to you all so again I would say PCH continues to be the area, where we have seen the most pull.
Pull back and again on the consumer health side of that business.
Awesome Thats helpful. Thank you.
Our next question comes from Dave Windley with Jefferies. Please go ahead Dave.
Hi, Thanks, Good morning, Thanks for taking my question so.
Tom I wanted to just try to focus a little bit on gene therapy, and some of your commentary around.
The contract asset and the and the conversion of that so if we presume.
That that's rep gets good news and gets approved and you continue there.
You say youll move the contract asset into into billed receivable and then I guess from a commercial product <unk>.
Standpoint, it would then become a batch revenue rec batch delivery revenue recognition.
Model I guess I'm trying to.
Your stand at the point at which that gets approved and you've been recognizing revenue in the contract asset.
Do you then have a period where.
Theres not revenue recognition until you get the next batch done and deliver that because it's now an approved product can you walk us through that a little bit.
Yes, it's a.
Great question, and one that we continue to wrestle with and work through internally here I would say there is various different ways that we can address in the event that we do see the selective product essentially moving.
Two commercial there'll be scenario that you.
<unk> laid out which would be a movement from percent completion as it's done on the development cycle to batch release upon commercialization is certainly one of those alternatives.
There are other alternatives as well that would align to U S GAAP and ASC 606 guidance around revenue recognition.
And we are pursuing those and looking at those with our auditor in conjunction with our auditor UI to ensure that we have.
The best possible scenario as outlined in the situation in which you highlighted if we were to move to batch release being driving the recognition and the cycle time remains as long as it is from that production cycle. It wouldnt relate it would create.
A period of an air pocket as you mentioned from a revenue standpoint.
That's the piece that we essentially need to continue to.
Look at so as we know more around this and come to a determination one whether or not that commercial approvals granted in late may time period.
Again being outside of our control obviously, we'll communicate more to the street around us I would say regardless of what happens on may 29th.
The impact to us in fiscal 'twenty. Three is is is minimal if at all right because what we will have at that point in time as the majority of revenue that we would be recognizing in that June time period being batches that are essentially already in flight that are essentially kicked off while the product was still considered a development product.
So many moving pieces around this Dave I think you are asking the right questions. These are the types of things, we're looking at internally and when we come to a determination on exactly.
What that revenue recognition profile is going to look like for this particular product given the binary event associated with the approval, where we will ensure that that is properly communicated so that so that you all understand how to model it.
Hi.
I appreciate that thank you my follow up question. Alessandro is for you you mentioned in your prepared remarks.
Some recent successful regulatory reviews.
I was going to ask her to give you the opportunity to maybe elaborate on that going back a little bit further you've obviously had some some fairly high profile 480, threes that that probably caused some angst.
With management and trying to address those in energy and so forth and so in the context of those things I guess I wanted to understand what you you you emphasize catalyst's quality I wanted to understand are your aspirations to eliminate these 480 threes or deal with them.
You can when they happen.
I'm, just wanting to understand where the aspirations are on the track record relative to regulatory review. Thank you.
Sure look this is a great question and thanks for asking it. So look first of all I would say.
As you said.
What are your visa or <unk>.
Not uncommon.
The industry, especially in some type of manufacturing operations is surely.
That Idaho patients up to one debt to Cds.
And the most frequently.
Just to be clear, we don't plan portfolio agencies that we work a very odd across our quality management system with our leadership without people without operational excellence.
Spectation set to avoid the need for <unk> to the extent it's possible. However.
These are public information so you see that it is a.
Shadow dose inspections, which show, resulting foot 80 to visa.
True for all the players seem to the into the industry.
It is as important as trying to prevent them about giving them more important tie you respond to those observations.
In a in a thorough <unk> ballistic week meeting to corrective actions and some of those corrective actions sexually most.
Most of them yields to improve operation on the other end of them. So.
That's one part of the answer the other part of the answer to that which I will I want to stress is that as leasing how many times. The government received a regular inspection sold the time non <unk> capital cases happen to be as you said.
Visible, but that I inspections, all the time and we are pretty pleased with our track record.
Of inspections, both from share and.
Ratio of the ones, resulting in Florida, but also we can get the number of operations that that only money in those four adv. So look I know, it's been an element of noise in the last few months about the.
Given that the outcome of those inspections here he's heading to plus the ongoing track record on the on the further inspection. So we received that we feel pretty confident about our quality management system and our operational excellence.
Yeah.
That's helpful. Thank you.
The next question comes from Matt Smoke of William Blair. Please go ahead ma'am.
Alright, thanks for taking our questions I just wanted to touch on some of the dynamics I know last quarter, you pointed to some cash conscious decision, making from customers on the biologic side. Just curious if your conversations really changed here at all given some of the positive developments in the market and what are customers, telling you about their conviction in their ability to go out and raise funds and how does.
That compared to when.
When we spoke this time at the end of last.
Last year.
Yes sure look thanks for the question I believe look we need to separate it out in our consideration of relative considerations in absolute consideration I will tell you that in absolute terms, our market could be continuing to be a very exciting market. Our sharing these market continues to be one of the leading shares into the market that we continue to see very nice wins across.
The board a lot offerings.
Some of the considerations, sometimes that in relative terms in terms of what Walter what could have been.
In general terms that were very very happy about the market that we had albeit at a gain.
The funding is being should lead to using it.
But.
You look at the growth in our core business, our non COVID-19 business, you're still seeing the business growing above market.
To be honest in the in the in the mid teens and when you look at the biologics specifically, even more exciting than that so.
I will tell you.
The market that need the correct a little bit about the steel supporting a very exciting growth perspective for the future.
And it's good to hear thank you and then just a quick follow up for me around the Brussels facility I know last in fiscal year 2022 is closed down obviously is for six months just wondering if theres any way any detail you can provide to help us think about the margin tailwind. That's what's one time from that factory being online for the full year.
Thank you.
Yes. This is process is a relatively small facility for us overall, but it's certainly as I mentioned in my prepared remarks, Matt.
Max provides a little bit of a tailwind for us here both from a revenue and a margin standpoint as you mentioned the site was taken offline in the second half.
<unk> of the fiscal year. So it is up against.
A relatively easy comp, but again Brussels.
Not a significant site in terms of size from a revenue and profitability contribution to the company.
Got it thanks.
Our next question comes from Paul Knight with Keybanc. Please go ahead Paul.
Thanks, Alessandro and Tom and Paul on the on the inventory discussion earlier or you finding that you can effectively destock now because of better supply chain conditions as well as.
Normalized customer demand.
So I would say Paul that we're seeing pockets of improvement and again, we are many different.
Components and inputs.
For the various different types of products that we manufacture across our biologics and PCH segments I would say.
There are areas of improvement.
But there are certainly areas, especially on the PC side of the business, where we do continue to see some challenges from a supply chain standpoint that factored into our decision to continue to remain I would say slightly elevated or elevated from a from an inventory standpoint.
Were very specific to say that in the short term. This is going to be a tailwind opportunity for us when we have the comfort in being able to pull back on some of those higher levels of inventory are more likely to be a meaningful contributor to free cash flow in 'twenty. Four then I would say it is in 'twenty three although as we get into the back half of the year, we should see some modest improvement yes.
In short the DS asset I believe that our level of comfort in destocking desiring by amount of opportunity because any DS and small molecule given that that the geographical source. These components.
That is a little bit of a difference there.
And then last question would be you had mentioned at the beginning Allison drove the build finish market very good.
And what are the dynamics, creating these positive trends in fill finisher.
And I believe year, one top 123 in the world.
Yes, sure look number one we are very very excited about our position in that market that being one of the top players is truly one of the players that before that has moved into the state of the art technology, which is fill and finish on that isolator. So that is truly creating a competitive advantage.
Catherine that surely continue to increase our share of the most attractive molecules a photo from a <unk> standpoint.
I believe that the positive trends are two folds number one.
Pipeline itself, each lending good-naturedly towards feeling finish it because you are looking at assets in the pipeline which are.
You know you cannot put in the oral solid so they are lending themselves multiple feeder fish and because there is a tendency to self administration, they lend themselves more towards.
Okay.
<unk> injector, so that's one dynamic filled the pipeline.
The pipeline that's one dynamic the other one.
As related to the increased movement of our critical products to underwrite the radar technology.
The regulatory environment.
He is an evolving environment.
And so the expectations when it comes to steady the assurance is really suggesting that.
Going forward the preferred.
By far the preferred.
We are doing this is going to be on the regulator and for that that will be at <unk> position.
Great assets already online and many more coming online in the next 18 months.
Thank you.
Yeah.
Our next question comes from Tejas Savant with Morgan Stanley . Please go ahead.
Hey, guys good morning.
Tom just a quick.
Up on the margin trajectory into the back half of the year.
It sounds like based on your comments you are expecting a pretty significant sequential step up in EBITDA dollars into the fourth quarter here.
The right way to think about it essentially just the fact that you know you'll get over $150 million essentially in Covid revenue in the fourth quarter and very little in the third quarter.
And an ex Covid can you just point us to sort of how you see that that margin line evolving between the third and fourth quarter yet.
Sure I think your point is spot on and certainly we will see COVID-19 in that range as you as you mentioned the $150 million plus after a minimal contribution in Q3 that will certainly drive part of the margin story, but I was also very specific in.
In discussing the ramp up of a major gene therapy program as.
As we've talked about being late in the third quarter here and having a full quarter of ramped contribution to us from a.
From a fourth quarter standpoint, and given the operating leverage you can see from the utilization of assets there as well as the just the normal attractive margins that you see related to the gene therapy side of our business and biologics overall, you can see that step up I would say from a non COVID-19 standpoint, if you were to strip out COVID-19 out of all of our quarters, you would see a <unk>.
The reality profile that very closely mirrors, what our historical seasonality has been pre COVID-19, which is that step up in the second quarter versus Q1 levels. Then a step up to Q3, but then ultimately a significant ramp in Q4 ahead of the summer months and some of the I would say downtime that we see.
Across our customers.
Our customers' networks as well as our own network.
Related to abnormal.
Maintenance related activities that you see in the summer months there and.
Taking up sites offline. So so that's certainly all contributing to that significant step up we see in the fourth quarter.
Got it that's super helpful.
And then one of the two parter on the top line actually perhaps for Alessandra here. So first on <unk>. How confident are you that the assets can return to those sort of 20% growth level that you'd talked about at the time of the acquisition or do you think of that perhaps is being partially driven by update.
During the pandemic and perhaps now normalizes to a slightly lower level and then the second part of my question is on the biologics front.
As you think about potentially a $400 million to $450 million step down into fiscal 'twenty four from Goldman.
We'll also be lapping some of these.
Pre approval sort of like inventory builds or is their appetite et cetera.
Do you think about framing the growth for the biologics segment as it sort of Anniversaried those dynamics.
So look.
For for the better one.
This is a market that we are looking at very very closely.
Great.
The overall Vms market.
As it decreased in fact tinder in 2022, so we are really.
Trying to get to together with or without customers with our biggest customers to try and understand a little bit more.
Fundamental dynamics are.
About.
Above these market have not changed meaning that that he said that he has a tendency of people to go to.
Self self.
Preventative medicine, so to speak well wherever you want to call it and truly <unk> dosage form so the fundamentals out there.
Clearly the market is going through correction, both because of the end market demand, which is contracted in 2022 and because of destocking for cash consideration. So so we have seen.
Should we clearly.
A disappointing trend.
In the last few quarters.
We expect these to continue through our fiscal year, but at the moment that there are there are signals that at some point in the later part of this kind of end of the year.
The correction of inventory could go could go out that we will be back instead of being at the end market demand.
With regards of the of the 2000 2040 is a little bit too early to have any consideration about it. So as we are going to continue to to walk through the fiscal year, we're going to keep you.
Updated about these but I would say that we continue to be excited about the partnerships, we have with the key customers going into the future.
Got it thank you.
Our next question comes from Sean Dodge with RBC capital markets. Please go ahead.
Yes. Thanks.
Morning.
Tom you mentioned, the $75 million to $85 million.
Head count related savings, but then said there could be some additional beyond that that could be in the tens of millions of dollars from other efficiency and I think you said procurement initiatives.
Is there any more kind of <unk>.
<unk> sure on the timelines for the latter when do you expect the benefits from from the other efficiency and procurement initiatives begin to accrue.
Yes, I think it's I think it's the same timing.
What we're seeing from a head count standpoint, the head count initiatives said, we were up actually by the end of the.
The end of the calendar year to be able to see the full benefit in the second half of fiscal year and the full annualized savings over the calendar 2023, I would say it's been the same for some of the non employee related.
Initiatives in procurement.
Initiatives that we've had underway we.
We did highlight the tens of millions, but I would say there will be a partial contribution in fiscal 'twenty three.
Assumed in that.
Carryover of that being into the first half of fiscal 'twenty for us. So again, we're looking at that from the same lens on a calendar year basis.
Okay, and just to clarify you said about half of that annual run rate you expect to capture in the second half of your fiscal 'twenty three.
It looks like some of these head count reductions.
After the beginning of Q2 was there any amount of of the savings reflected in the most recent your fiscal second quarter.
No there was no no material impact from these initiatives in the second quarter. They were actually I would say late.
In the second quarter some of the cash.
Costs associated with those exits were contemplated in the second quarter. Some of that may perhaps carry into Q3 as well you'll see that as an add back to adjusted EBITDA for the restructuring line.
Line item, but the real impact from a savings standpoint will be realized in the second half of the fiscal year and then get carry into <unk>.
First half of 'twenty four.
Okay.
Very helpful. Thank you.
Okay.
The next question comes from Justin <unk>.
Keybanc. Please go ahead.
Hey, good morning, everyone. So.
Just based on the.
The comments on PC agents coming in a little lighter.
Would imply the biologics is coming in stronger can you can you just help us bridge the.
The non COVID-19 growth in the second half of the year end.
Some of the some of the key drivers there.
Yes, Justin we really didn't highlight any material change to the non COVID-19 biologics growth I would say, it's very similar to what was assumed in what we saw as part of our last guidance the real change that offsets the call. The pullback on the PCH side is the over performance on the corporate portfolio. As we mentioned Covid was originally assumed to be approximately five <unk>.
Third and $50 million of revenue for us in our prior guidance and based on the orders that we have now related to our fourth quarter.
As the customer ramps up for the fall booster season, we now expect COVID-19 revenue to be.
To be more than $600 million in the year. So it's really the COVID-19 revenue that's offsetting the pullback on P. C H.
Okay got it and then just you talked about tech transfers over the last couple of quarters.
<unk>.
Have those have those started or are they contributing yet and then just with the commentary on the additional suites and Harman are they.
When are those coming online is that is that a.
Is that a fiscal year event or is that a calendar year event, just a little more clarity there would be helpful.
Yes look so let me start from the latter part of your question. So yes additional suites are coming online as we speak.
And as we have already shared.
The level of utilization.
He's a he's ramping will be ramping up in the next few quarters right. So.
I believe that you know.
In Q3, you're going to see a little bit of a balancing factor because yes, you don't pick up a yield so.
The utilization by you'd also ramping up the costs associated with dining and training. The people that are required for these for these suites.
As we said that we would remain.
Betty.
<unk> optimistic.
That the gene therapy demand in viral vector manufacturing going forward not only with direct up but also across the spectrum of all of our clients is a pretty good space for us.
With regard to the Congress districts.
<unk> continued to progress.
There are.
Several programs at the same time progressing <unk>.
And I would say that we are.
Pleased with the kind of program with transferring gain and actually these programs will continue to contribute.
Two our talk product the growth into the future.
Thank you I'll jump jump back in queue.
Our next question comes from Derik Debruin of Bank of America. Please go ahead Derek.
Hey, good afternoon or good morning.
Can we talk a little bit about this the raptor.
Contract I'm, just curious was that contemplated in sort of like the ramp up contemplated in your original fiscal.
Fiscal 'twenty three guide or is what Youre seeing now more incremental to what you had originally expected.
So related to <unk>. This is playing out as we had anticipated for the fiscal year here.
As I mentioned the <unk> date in late May where depending on where that lands that doesn't have a material change for us regardless of whether that's an approval or not in the current fiscal year and the outcome of that will have more of an impact for us on fiscal 'twenty four.
But I would say nothing materially different from what we had assumed based on the.
This has always been a program that obviously, our customer, but we have been bullish on as well.
No real change in outlook there in terms of what the the 23 impact.
Is related to the to the announcement here.
Just I just want to say that the buffet buoyed the Nichols.
It's a little bit wider and then these are only programs. So they have a.
Some capacity that we dedicate to them into our facility and they can allocate to different programs to both the clinical in preparation for commercial as a.
They see the data that our plants are developing so.
So that is that is more than just DMT here.
Got it and I wanted to follow up on <unk>.
<unk> question on the.
PCH business I mean, it does look like that.
I've looked at third party research on the gummies market it looks like Thats more like a 12, 13% sort of my growth market from what I've been able to dig up I mean, when you look at that.
10% Guide you put out for the long term and the PCH.
How critical is the gummy segment going back to the 20% range is sort of like get to that number.
So local number one I would tell you that we never assume a business going forward that to grow at the top end of anything just so so we did and assuming our in our story there that 20% assumption for sure right. So we tend to be pretty conservative on these <unk>.
Forecast because as you know all things might changing needs in these markets. So that's the first consideration. The second consideration is that in terms of the PCH story that is much more to PCH adjust to got thing.
The economy. So when you look at the demand we are seeing if it was in my remarks that on the diabetes dosage form.
Just exceptional demand and I used the word exceptional not by chance that mistake. We are seeing a demand that is far exceeding capacity. So we are.
Building capacity as fast as we can we gotta be opening soon on North America, not very soon but sometimes in the next few quarters or North America.
Facility for diabetes.
Because we need that additional facility we have installed the recently last year, we have installed an additional line in diabetes and we are working on a number of operational excellence programs to debottleneck capacity, there, but there are some very very reasonable products.
Each are growing very fast in that size is four months. So that is one area that is surely contributing to the growth story OTC age and let me remind you. That's one of the most profitable business of the catheter into Nashville, because you'll be open in a ball, but some other pieces even considering biologics.
And we did with regards of the other parts of TCA should look clearly PTH, especially in the in.
In the pharmaceutical supply is very much dependent on the timing of some approvals and the timing of some of the and the launch of some of these approvals. So it tends to be a little bit lumpy at times, but the way you look at the in the in the in the in the in the three to five years horizon.
That is a business that is.
A very exciting pipeline.
To support growth.
Yes.
Thank you.
Our next question comes from John saw that UBS. Please go ahead Kevin.
Thanks for taking the question.
Just with the increase in the cobot guidance in that greater than $600 million and strength in <unk>.
<unk>.
When you can provide some color on what the endemic Covid run rate looks here, even beyond fiscal 'twenty, three and what should we how should we think about this long term.
Well I think it's a difficult question to answer Jon with so we're going to hold back from giving any more specifics around what fiscal 'twenty four it could look like here, but I think the relationship and the continued relationship and strategic partnership that's been.
Extended.
As well as expanded with Madonna I think speaks to.
The future that we believe exists for Covid vaccine related revenue.
In the future for us, but again, we are going to fall short of giving any specific run rates as we exit this year in terms of what that could look like for us in 'twenty four.
Hey can I add one comment to this one look at the fact that we are bringing online more assets into the network because surely will contribute to the ability of running gun endemic business with better productivity and profitability.
Thanks, and if I could sneak in a follow up the company's previously stated I think working on greater than 150.
Supported gene therapy product any update just on the number of programs here and just how we think about with the additional capacity coming on online in that non sort of the opportunity with some of these programs.
I wouldn't I wouldn't say, there's any change to that we continue to work on about 150 development programs across that part of the business that's what.
That's justified further.
Capacity expansions within that within that space and I would say not only we are pleased with the number of programs. We work on on the gene therapy side of the business at all but also the progression and maturity of those that continue to move from earlier phase later phase and obviously the <unk> relationship.
And program or programs is just one example of that so again feel very good about about the growth prospects and opportunities in this business.
Our next question comes from Adam David with Baird. Please go ahead Evan.
Okay.
Just one for me because John asked.
But.
This is a cleanup.
Last quarter, you said you had some efficiency initiatives.
That were in flight and then your last updated guidance. So I just wanted to be perfectly clear that 75 to 85.
Efficiency actions that you can.
Noted today is that is that that prior program or is that incremental.
Edition and additional cost savings to your guide today.
No. These were these were all originally contemplated we felt the need to be able to provide some additional disclosure and meat on the bone. If you will related to the cost savings initiatives 700 head counts, we've talked about were difficult for us to talk through at the time of our last guidance, because we werent, we didnt execute on those.
But now we've since executed on that through the end of the calendar year. So we will see half of that run rate savings in the current fiscal year with the remaining half to be carried into the first half. So you should look at that annualized number across calendar 'twenty three versus our fiscal year and I would say the further commentary around the tens of millions of dollars related to other cost.
Savings initiatives efficiencies and procurement programs. We're also contemplated as part of the original guide.
Yes.
As expected I appreciate that clarification and that's it for me.
Okay got it.
Our final question comes from Jack Meehan of Nephron Research. Please go ahead Jack.
Thank you good morning.
So I wanted to talk about core organic growth it was over 20% last quarter.
It's 4% this quarter can you frame for us the math on some of the moving parts that led to the quarterly slowdown and then for <unk> is the reacceleration to over 20% happening right now I'm just talking about your visibility into that.
Sure. So Jack I think we've said in.
Alessandro his comments that one of the things we needed to do was prioritize our COVID-19 related program related to the emergency use authorization of the pediatric.
Covid vaccine over.
Non COVID-19 related revenue out of our Bloomington facility.
I'm not going to be in a position to tell you what our non COVID-19 growth would have been in the second quarter.
If we werent prioritizing that program, but that certainly had a significant impact in why we were only able to achieve 4% non COVID-19 growth.
In Q2 and.
And 12% non COVID-19 growth in Q2 for the biologics business, but but.
It's not necessarily the same.
That's in lines that are being utilized but it certainly the same operations and quality folks that we have in terms of.
Put it here.
Time and efforts around releasing of batches. So that certainly played into why we had a depressed non COVID-19 related growth in the second quarter. So I think returning in the in the third quarter back to non COVID-19 levels that we have seen through the first quarter of the year is as you know what I would consider to be.
You know normal normal course, or a low bar based on what we've been able to show.
And again the uptick in Covid related revenue that we expect to see in the fourth quarter is really offsetting.
Pull back on the PCH side of the business, where we continue to experience headwinds, particularly in consumer health.
Got it.
I wanted to try and the margin one more time, just looking at the fourth quarter your guidance in the commentary I think it implies for Q EBITDA is about 40% of the full year and look over the last five years, it's about 33%.
So just help us with the math again I know there are some things that are really stepping up in the fourth quarter. It's just much more pronounced and I think we've seen previously.
I think your numbers are probably close maybe I'll, maybe I'd say, it's a little bit on the.
But on the high side in terms of the Q4 contribution, but again not materially.
Different I would say.
Three things I would point to one the COVID-19 related revenue here is going to be sizable as we've already talked as we've already talked about the ramp up on the gene therapy side of the business related to a major customer program that we've talked about here of new capacity, that's going to be coming online in the third quarter, it's going to be utilized this is going to be by far the strongest gene therapy.
We've ever seen in the fourth quarter, so very difficult to compare that to historical years, where we werent seeing gene therapy contributions to the levels that we'll see here around the business.
Isn't it the area that I would say I would factor in and then just a normal level of seasonality that we see around the PCH side of the business around Q4 heading into the summer shutdown periods is another item that takes into consideration here.
Lastly, I would say the Brussels dynamic for us in the prior year. If we're looking at this as certainly.
I would say a.
A headwind that we had in the prior year. So the natural lift up that we'll see here for the fourth quarter that was a business that was shut down a facility that was shut down for us that'll be that'll be up and running here as well. So I think all of those things factor into that.
The margin profile, we expect to see in the fourth quarter and lastly, I would say I would just reiterate that this was that the demand is there right the level of visibility that we have to volume.
Tier or demand for the for the second half of the year and even the fourth quarter is as high as it comes down to the levels of execution that we're able to deliver upon across our network of sites.
Thank you Tom.
Thank you for the questions. We have for today, so I'll kind of go back to Alessandra for concluding remarks.
Thank you everyone for taking the time to join our call and your continued support of Covenant.
Thank you.
Thank you everyone for joining us today. This concludes our call and you may now disconnect your lines.